Join our in-depth discussion about the challenges of HIV treatment, the importance of adherence to antiretroviral therapy, and how long-acting ART can improve treatment outcomes.
Join our in-depth discussion about the challenges of HIV treatment, the importance of adherence to antiretroviral therapy, and how long-acting ART can improve treatment outcomes.
An expert discusses the HIV treatment option Cabenuva, and explains why this is a more convenient way to deliver long-acting antiretroviral therapy to patients who either do not want to take a daily pill, or who are just wanting to break the...
An expert discusses the HIV treatment option Cabenuva, and explains why this is a more convenient way to deliver long-acting antiretroviral therapy to patients who either do not want to take a daily pill, or who are just wanting to break the...
Gary Owens, MD, president of Gary Owens Associates, reviews what payers should know about cabotegravir as it hits the market, as well as how future treatment options could impact costs and patient care.
Gary Owens, MD, president of Gary Owens Associates, reviews what payers should know about cabotegravir as it hits the market, as well as how future treatment options could impact costs and patient care.
Gary Owens, MD, president of Gary Owens Associates, discusses the financial burdens of HIV and the challenges payers face when covering this patient population.
Gary Owens, MD, president of Gary Owens Associates, discusses the financial burdens of HIV and the challenges payers face when covering this patient population.
In part two of this podcast series, Daniel Lee, MD, clinical director, Pacific AIDS Education Training Center HIV Learning Network, and director, Owen Lipid/Lipodystrophy Clinic, University of California–San Diego, discusses the therapies...
In part two of this podcast series, Daniel Lee, MD, clinical director, Pacific AIDS Education Training Center HIV Learning Network, and director, Owen Lipid/Lipodystrophy Clinic, University of California–San Diego, discusses the therapies...
In part one of this podcast series, Daniel Lee, MD, clinical director, Pacific AIDS Education Training Center HIV Learning Network, and director, Owen Lipid/Lipodystrophy Clinic, University of California–San Diego, offers insight into the...
In part one of this podcast series, Daniel Lee, MD, clinical director, Pacific AIDS Education Training Center HIV Learning Network, and director, Owen Lipid/Lipodystrophy Clinic, University of California–San Diego, offers insight into the...
Diana Finkel, DO, director, Infectious Disease Fellowship Program, Rutgers New Jersey Medical School, discusses current issues in HIV care in the United States, including barriers to access for transgender patients, how COVID-19 impacted...
Diana Finkel, DO, director, Infectious Disease Fellowship Program, Rutgers New Jersey Medical School, discusses current issues in HIV care in the United States, including barriers to access for transgender patients, how COVID-19 impacted...
Chris Beyrer, MD, infectious disease epidemiologist and professor at Johns Hopkins Bloomberg School of Public Health, discusses fundamental barriers within HIV care, and how the US health system can better manage the HIV epidemic, which...
Chris Beyrer, MD, infectious disease epidemiologist and professor at Johns Hopkins Bloomberg School of Public Health, discusses fundamental barriers within HIV care, and how the US health system can better manage the HIV epidemic, which...
Chris Beyrer, MD, infectious disease epidemiologist and professor at Johns Hopkins Bloomberg School of Public Health, breaks down current rates of HIV across the United States as well as the challenges linked with controlling this...
Chris Beyrer, MD, infectious disease epidemiologist and professor at Johns Hopkins Bloomberg School of Public Health, breaks down current rates of HIV across the United States as well as the challenges linked with controlling this...
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to...
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
